ArticleScientific reports2025
Investigation of bioactivity, biocompatibility, and antibacterial properties of a hydroxyapatite-enhanced nanocomposite for dental applications.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prolonged setting duration of mineral trioxide aggregate (MTA) constitutes one of its principal limitations. In contrast, Nano Fast Cement (NFC) emerges as an innovative nanocomposite characterized by a rapid setting time. To develop an outstanding dental filler, hydroxyapatite nanoparticles (NHA) were incorporated into NFC to evaluate their effects on setting time, biocompatibility, bioactivity, and antibacterial properties. Specimens containing 0, 10, and 20 weight% (W%) hydroxyapatite were subjected to assessment utilizing the MTT assay for cytotoxicity, the Gilmore needle for measuring setting time, scanning electron microscopy (SEM) and X-ray diffraction (XRD) for microstructural and phase analyses, as well as antibacterial evaluations against Enterococcus faecalis (PTCC 1394). Phase and microstructural investigations confirmed the formation of hydroxyapatite. The addition of 10 and 20 W% hydroxyapatite significantly improved the specimens' bioactivity while reducing toxicity by 20%. An increase in hydroxyapatite content corresponded with a greater enhancement in bioactivity and a further reduction in toxicity. These findings indicate that the addition of NHA did not detrimentally affect the physical properties of NFC; rather, it augmented the filler's bioactivity in vitro. Furthermore, the nanocomposite containing a higher concentration of NHA exhibited superior inhibition of E. faecalis compared to NFC in minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) (p-value < 0.001).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.